BioCryst Upgraded To Outperform
Rodman & Renshaw has upgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) from Market Perform to Market Outperform with a $7 price target.
BioCryst Pharmaceuticals closed yesterday at $4.82.
Is AAPL a Buy, Sell or Hold? Click Here.







